DK1492539T3 - Statin-terapi til forögelse af kognitiv funktion - Google Patents
Statin-terapi til forögelse af kognitiv funktionInfo
- Publication number
- DK1492539T3 DK1492539T3 DK03745196T DK03745196T DK1492539T3 DK 1492539 T3 DK1492539 T3 DK 1492539T3 DK 03745196 T DK03745196 T DK 03745196T DK 03745196 T DK03745196 T DK 03745196T DK 1492539 T3 DK1492539 T3 DK 1492539T3
- Authority
- DK
- Denmark
- Prior art keywords
- cognitive function
- statin
- statin therapy
- enhance cognitive
- galantamine
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 4
- 206010012289 Dementia Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229960003980 galantamine Drugs 0.000 abstract 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36928502P | 2002-04-02 | 2002-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1492539T3 true DK1492539T3 (da) | 2006-10-30 |
Family
ID=28675573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03745196T DK1492539T3 (da) | 2002-04-02 | 2003-03-28 | Statin-terapi til forögelse af kognitiv funktion |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1492539B1 (da) |
| JP (1) | JP2005525391A (da) |
| KR (1) | KR100986194B1 (da) |
| CN (1) | CN100528164C (da) |
| AT (1) | ATE331523T1 (da) |
| AU (1) | AU2003226753B2 (da) |
| BR (1) | BR0308293A (da) |
| CA (1) | CA2480275C (da) |
| CY (1) | CY1105545T1 (da) |
| DE (1) | DE60306503T2 (da) |
| DK (1) | DK1492539T3 (da) |
| EA (1) | EA013069B1 (da) |
| ES (1) | ES2268393T3 (da) |
| IL (2) | IL164317A0 (da) |
| MX (1) | MXPA04009535A (da) |
| NO (1) | NO20044698L (da) |
| NZ (1) | NZ536111A (da) |
| PL (1) | PL211160B1 (da) |
| PT (1) | PT1492539E (da) |
| UA (1) | UA79605C2 (da) |
| WO (1) | WO2003082298A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| EP1737539A1 (en) * | 2004-04-14 | 2007-01-03 | Warner-Lambert Company LLC | Therapeutic combination for treatment of alzheimers disease |
| EP1604686A1 (en) * | 2004-06-08 | 2005-12-14 | Axonyx, Inc. | Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| US20160303146A1 (en) * | 2013-12-13 | 2016-10-20 | David A. TABACZYNSKI | Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
-
2003
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko not_active Expired - Fee Related
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en not_active Ceased
- 2003-03-28 EP EP03745196A patent/EP1492539B1/en not_active Expired - Lifetime
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
-
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
-
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL211160B1 (pl) | 2012-04-30 |
| CN100528164C (zh) | 2009-08-19 |
| PT1492539E (pt) | 2006-11-30 |
| KR100986194B1 (ko) | 2010-10-07 |
| DE60306503T2 (de) | 2007-06-21 |
| PL371551A1 (en) | 2005-06-27 |
| CY1105545T1 (el) | 2010-07-28 |
| IL164317A0 (en) | 2005-12-18 |
| AU2003226753B2 (en) | 2007-06-28 |
| AU2003226753A1 (en) | 2003-10-13 |
| NZ536111A (en) | 2006-03-31 |
| NO20044698L (no) | 2004-10-29 |
| ATE331523T1 (de) | 2006-07-15 |
| EA200401295A1 (ru) | 2005-02-24 |
| DE60306503D1 (de) | 2006-08-10 |
| HK1079688A1 (zh) | 2006-04-13 |
| JP2005525391A (ja) | 2005-08-25 |
| CN1642555A (zh) | 2005-07-20 |
| MXPA04009535A (es) | 2005-01-25 |
| EP1492539B1 (en) | 2006-06-28 |
| UA79605C2 (en) | 2007-07-10 |
| EP1492539A1 (en) | 2005-01-05 |
| ES2268393T3 (es) | 2007-03-16 |
| BR0308293A (pt) | 2004-12-28 |
| KR20040096608A (ko) | 2004-11-16 |
| IL164317A (en) | 2010-04-29 |
| EA013069B1 (ru) | 2010-02-26 |
| CA2480275C (en) | 2011-08-16 |
| WO2003082298A1 (en) | 2003-10-09 |
| CA2480275A1 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE269846T1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
| BG106095A (bg) | Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| SI1546127T1 (sl) | Novi pirimidinamidni derivati in njihova uporaba | |
| ATE268174T1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| DE602004031631D1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| BG105342A (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
| ATE331523T1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
| ATE404192T1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
| ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo | |
| DE60122764D1 (de) | Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen | |
| ATE334675T1 (de) | Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole | |
| ATE353221T1 (de) | Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa |